menu

Updates in Head and Neck Cancer Treatment: Integrating Checkpoint Inhibitor Therapy to Improve Outcomes

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Updates in Head and Neck Cancer Treatment: Integrating Checkpoint Inhibitor Therapy to Improve Outcomes

close
3 chapters
Play All
0.25 credits
15 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Head and neck squamous cell carcinomas (HNSCC) represent a significant healthcare burden due to associated morbidity and mortality. Most patients survive less than a year after diagnosis and report a poor quality of life. Tune in to this chapterized content as two leading experts, Drs. Ezra Cohen and Barbara Burtness, discuss recent clinical trial data and strategies to improve sequencing and treatment selection. Find out how checkpoint inhibitors are shifting the treatment landscape of HNSCC and what this means for your patients. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Ezra Cohen, MD
    Professor of Medicine
    University of California, San Diego Moores Cancer Center
    La Jolla, CA 

    Ownership Interest: Kinnate Biopharma and Primmune Therapeutics
    Consulting Fees: Bayer; Eisai; Gilead; Janssen; Kinnate Biopharma; Merck; Mirati; MSD; Regeneron; Roche
    Board of Directors: PsiOxus Therapeutics

    Faculty:
    Barbara Burtness, MD
    Professor of Medicine
    Co-Leader, Developmental Therapeutics Program
    Yale Cancer Center, Yale School of Medicine
    New Haven, CT

    Consulting Fees: ALX Oncology, AstraZeneca, Cue Biopharma, Debio, Genetech, Hookipa, IO Biotech, Kura, MacroGenics, Merck, Merck KGaA, Nanobiotix, Nektar, Nuvelution

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Estelle Perera has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate key clinical trial data on checkpoint inhibitor therapy in different settings of HNSCC
    • Identify patient subsets that will benefit from frontline and later lines of checkpoint inhibitor therapy
    • Formulate strategies to adequately sequence and optimize checkpoint inhibitor therapy to improve outcomes in HNSCC
  • Target Audience

    This activity is designed to meet the educational needs of community oncologists, oncology NPs/PAs, and oncology nurses as well as radiologists, surgeons, and pathologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Head and neck squamous cell carcinomas (HNSCC) represent a significant healthcare burden due to associated morbidity and mortality. Most patients survive less than a year after diagnosis and report a poor quality of life. Tune in to this chapterized content as two leading experts, Drs. Ezra Cohen and Barbara Burtness, discuss recent clinical trial data and strategies to improve sequencing and treatment selection. Find out how checkpoint inhibitors are shifting the treatment landscape of HNSCC and what this means for your patients. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Ezra Cohen, MD
    Professor of Medicine
    University of California, San Diego Moores Cancer Center
    La Jolla, CA 

    Ownership Interest: Kinnate Biopharma and Primmune Therapeutics
    Consulting Fees: Bayer; Eisai; Gilead; Janssen; Kinnate Biopharma; Merck; Mirati; MSD; Regeneron; Roche
    Board of Directors: PsiOxus Therapeutics

    Faculty:
    Barbara Burtness, MD
    Professor of Medicine
    Co-Leader, Developmental Therapeutics Program
    Yale Cancer Center, Yale School of Medicine
    New Haven, CT

    Consulting Fees: ALX Oncology, AstraZeneca, Cue Biopharma, Debio, Genetech, Hookipa, IO Biotech, Kura, MacroGenics, Merck, Merck KGaA, Nanobiotix, Nektar, Nuvelution

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Estelle Perera has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate key clinical trial data on checkpoint inhibitor therapy in different settings of HNSCC
    • Identify patient subsets that will benefit from frontline and later lines of checkpoint inhibitor therapy
    • Formulate strategies to adequately sequence and optimize checkpoint inhibitor therapy to improve outcomes in HNSCC
  • Target Audience

    This activity is designed to meet the educational needs of community oncologists, oncology NPs/PAs, and oncology nurses as well as radiologists, surgeons, and pathologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule28 Oct 2021
Webpack App